A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use

American Journal of Gastroenterology

Volumn 100, Issue 8, 2005, Pages 1685-1693

  Lanas, Angel ^a   Perez Aisa, Maria Angeles ^a   Feu, Faust ^b   Ponce, Julio ^c   Saperas, Esteban ^b   Santolaria, Santos ^d   Rodrigo, Luis ^e   Balanzo, Joaquim ^f   Bajador, Eduardo ^g   Almela, Pedro ^c   Navarro, Jose M ^h   Carballo, Fernando ⁱ   Castro, Manuel ^j   Quintero, Enrique ^k  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL SAN JORGE   (Spain)

^e Hospital de Asturias   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL COSTA DEL SOL   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^j HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^k HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DIGESTIVE SYSTEM PERFORATION; DRUG INDUCED DISEASE; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; UPPER GASTROINTESTINAL TRACT; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; MIDDLE AGED; SPAIN; STATISTICS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SPAIN;

EID: 25644452810     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41833.x     Document Type: Article

References (34)

1. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: Increasing frequency of haemorrhage among older subjects. Gut 2002;50:460-464.
2. Perez-Aisa MA, Del Pino L, Siles M, et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 21(1):65-72.
3. Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use. Pain 2000;85:169-82.
4. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91.
5. Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: Overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52(4):600-8.
6. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. Br Med J 1995;311(6999):222-6.
7. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26 (suppl 56):18-24.
8. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
9. Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
10. Langman MJ, Morgan L, Worrall A. Use of antiinflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J 1985;290:347-9.
11. Wilcox CM, Alexander LN, Cotsonis GA, et al. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997;42:990-7.
12. Laine L, Connors LG, Reicin A, et al Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-92.
13. Ruiz M, Cirera Suarez L, Perez G, et al. Grupo CAMPARA. [Comparability between the ninth and tenth revisions of the International Classification of Diseases applied to coding causes of death in Spain]. Gac Sanit 2002;16(6):526-32.
14. Ruiz U, Acedo K, Buenaventura R, et al. Implementing total quality management in the Spanish health care system. Qual Assur Health Care 1992;4(1):43-59.
15. Paz Rodriguez-Perez M, de la Rosa Rodriguez G, Lopez-Madurga ET, et al. Variations on in-hospital mortality rates based on an administrative database aortocoronary bypass mortality rate. Med Clin (Barc) 2000;114(suppl 3):112-6.
16. Magee HF. The Hospital Data Project: comparing hospital activity within Europe. Eur J Publ Health 2003;13(suppl 3):73-9.
17. Steven H. Medicare severity-refined DRGs: An improved system. Available at http://www.irp.com.
18. Lilienfeld AM, Lilienfeld DE. Foundations of epidemiology. 2nd ed. New York: Oxford University Press; 1980.
19. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17.
20. Lanas A, Garcia Rodriguez LA. The use of coxibs does not increase the risk of upper gastrointestinal bleeding in common clinical practice. Gastroenterology 2003;124(4 suppl 1):A93.
21. Lanas A, Garcia Rodriguez LA. Grupo de Estudio del Tracto Digestivo Superior AEG. El uso de coxibs no se asocial a aumento del riesgo de hemorragia digestive alta. Gastroenterol Hepatol 2003;26:183.
22. Carmona L. Estudio EPISER. Madrid: Spanish Society of Rheumatology; 2000:141-54.
23. Kimmey MB, Lanas A. Appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004;19(suppl 1):60-5.
24. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343: 1520-8.
25. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
26. Silverstein FE, Graham DY, Senior JR, et al Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(4):241-9.
27. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989;32:926-32.
28. Moore RA. The hidden costs of arthritis treatment and the cost of new therapy-The burden of non-steroidal antiinflammatory drug gastropathy. Rheumatology (Oxford) 2002;41(suppl 1):7-15.
29. Singh G, Mithal A. Triadafilopoulos G age-adjusted hospitalization rates for complicated gastric and duodenal ulcers in the us: Have cox-2 specific inhibitors and PPIs made any difference? (Abstract). Gastroenterology 2004;126(4 suppl 2):1766.
30. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitors versus H2-antagonists: A meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001;15(7):917-26.
31. Lewis JD, Bilker WB, Brensinger C, et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: Relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002;97(10):2540-9.
32. Straus WL, Ofman JJ. Gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs. Gastroenterol Clin North 2001;30:895-920.
33. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: Did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003;98(7):1494-9.
34. Lanas A. Cost stratification of nonsteroidal antiinflammatory drug-associated gastrointestinal side effects. Med Clin 2000;114(suppl 3):46-53.